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ABSTRACT:  
Accumulation of amyloid fibrils from β2₋microglobulin (β2M) was first 
recognized as a characteristic osteoarticular complication in long-term 
hemodialysis (HD) patients and called “HD-related amyloidosis” (HRA). 
However, this syndrome can also be observed in end-stage renal diseases 
(ESRD) patients undergoing peritoneal dialysis, and even in patients with 
chronic renal failure before the initiation of dialytic therapy, suggesting that 
HD is not a direct cause but that accumulation of β2M or some β2M-
associated molecules in the body is a common pathogenesis. Currently the 
term “dialysis-related amyloidosis” (DRA) is widely used for β2M-amyloid 
(Aβ2M) amyloidosis associated with ESRD, though DRA patients consist 
mostly of those undergoing long-term HD.  
Factors other than β2M accumulation also play a role in the formation/local 
deposition of Aβ2M and disruption of tissue architecture. Conformational 
changes of β2M by misfolding/unfolding, and promoting/inhibitory effects 
induced by other co-existing molecules, advanced glycation and oxidation, 
and direct cell toxicity have also been documented. 
Two technological improvements of HD have been the keys to prevent the 
development and progression of DRA: the efficient removal of β2M by 
using high-flux membranes, high-volume convection and adsorptive 
column/membrane, as well asthe use of biocompatible membranes and 
dialysates (e.g. ultrapure and acetate-free dialysates) which have the 
minimized both inflammation and β2M production. 
Epidemiologically, a decrease in the incidence of DRA has recently been 
reported; however, longer survival of HD patients may contribute to the 
development of more DRA, though with a delayed onset. In this article, we 
describe the pathogenesis of DRA, the strategies developed for its 
prevention and minimization, and the favorable epidemiological data 
achieved by these efforts. 
 
Introduction 
Hemodialysis (HD)/dialysis-related amyloidosis (HRA/DRA) is a systemic 
amyloidosis that is mainly associated with osteoarticular lesions, including 
carpal tunnel syndrome (CTS), trigger finger (TF), spinal canal stenosis 
(SCS), destructive spondyloarthropathy (DSA), joint arthropathy and bone 
cysts. In 1975, Warren and Otieno reported a high incidence of CTS in HD 
patients (1); then, in 1980, amyloid deposition was recognized as being 
associated with CTS (2). In 1984, Kuntz et al reported DSA in HD patients 
(3). In 1985, Charra et al reported shoulder pain with amyloid deposition as 
well as CTS in long-term HD patients (4); in the same year, beta2-
microglobulin (β2M) was identified as the precursor protein of amyloid by 
Gejyo et al (5).  
Although β2M-amyloidosis (Aβ2M) had been observed in patients 
undergoing peritoneal dialysis, and even in patients with chronic renal 
failure before the initiation of dialytic therapy (6-8), HRA was recognized 
as a characteristic complication of long-term HD in the earlier era of HD 
which used low-flux membranes (i.e., cellulosic membranes such as 
cuprophan) with low biocompatibility of both the membrane and the 
dialysate. Currently the term DRA is widely used for all Aβ2M associated 
with end-stage renal diseases (ESRD), even though almost all DRA patients 
do undergo long-term HD. The removal of β2M from the body is almost 
wholly dependent on kidney function (5); therefore, greatly elevated 
circulating β2M in ESRD patients with disrupted kidney function is a 
prerequisite for developing DRA. 
Over the last two decades, even though the reduction of serum β2M level 
has not reached ideal levels, technological improvement of HD (i.e., high-
flux membrane, high-volume convection and ultrapure dialysate (UPD)) 
has certainly contributed to delay the onset of DRA and reduced its 
incidence and prevalence (9,10) (Fig. 1), which may in turn explain the 
observation that the most certain cause of DRA onset is a long dialysis 
vintage (10-12). 
In this article, we describe the pathogenesis of DRA, and the evidence of 
strategies (i.e., technical improvements in HD) that have succeeded in 
reducing DRA from the past up to today. We then discuss the current 
epidemiological data and factors associated with DRA. 
 
Pathogenesis of DRA: retention of β2M and amyloid fibril formation  
 β2M forms the beta chain of human leukocyte antigen (HLA) on all 
nucleated cells and is the causative protein of HRA/DRA. The production 
rate of β2M is constant, but increases in inflammation, infection and 
lymphoproliferative disorders. Most β2M can be removed by glomerular 
filtration and subsequent reabsorption and catabolism by proximal tubules. 
β2M accumulates when the removal rate falls below the production rate in 
ESRD patients, with serum β2M levels increasing up to 60-fold (5).  
 
Factors other than a high circulating level of β2M also play a role in the 
formation/local deposition of Aβ2M and disruption of tissue architecture. 
In in vitro studies, nucleation-dependent polymerization followed by an 
elongation process is required for Aβ2M formation. Conformational change 
by unfolding/misfolding of β2M is considered a first rate-determining step. 
Motomiya et al reported that β2M fragments having C-terminal unfolding, 
including a fragment lacking the first six amino acids (ΔN6β2M) (13), 
which has been recognized as an important amyloidogenic form, are 
essential for amyloidogenesis (14). Hereditary systemic amyloidosis due to 
the Asp76Asn-β2M variant—a new type of Aβ2M with normal renal 
function—also suggests the importance of conformational change for β2M 
amyloidogenesis (15). Naiki and coworkers (16,17), and other researchers 
(18) identified numerous promoters (i.e., type 1,2 collagen, 
glycosaminoglycan including heparin, proteoglycan, apolipoprotein E, 
lysophospholipid, free fatty acids and pentraxins (serum amyloid P 
component and C-reactive protein) and inhibitors (i.e., α2 macroglobulin 
and haptoglobin) ) of Aβ2M formation and elongation in in vitro studies. 
 
 For tissue damage caused by Aβ2M deposition, advanced glycation end-
products and advanced oxidation protein products, partially co-located on 
Aβ2M in uremic states, have been reported to induce proinflammatory 
effects; these are assumed to be triggered by bio-incompatible dialysis and 
contaminated dialysate. Recently, a new mechanism of direct cytotoxicity, 
by which endocytosed Aβ2M induced necrosis and apoptosis by disrupting 
endosomal/lysosomal alteration of membranes in synovial fibroblasts, was 
reported (19). 
 
Extracorporeal β2M removal in hemodialysis patients 
In the first two decades after HRA/DRA was first recognized in 1980, 
substantial technological improvements of HD in both permeability and 
biocompatibility of membranes and convection were made, especially in 
terms of satisfactory removal of circulating β2M. However, in the current 
era, the reduction of serum β2M has still not reached ideal levels. Renal 
transplantation is the ultimate option for bringing serum β2M close to a 
normal range with dramatic improvement of DRA symptoms, although 
radiologic (bone cysts) and histologic lesions do not disappear after long-
term follow-up (20).  
High-flux membrane 
Unmodified cellulosic membranes, such as cuprophane which is both 
impermeable and has low adsorptivity for β2M, have been recognized as a 
major direct culprit of HRA development. By contrast, high-flux 
membranes remove β2M at high rates and reduce early DRA onset in HD 
patients (12, 21-24). 
Membrane biocompatibility is assumed to be brought about by the 
adsorption characteristics of its materials. Indeed, adsorbed β2M amounts 
vary considerably depending on the material: namely, 
polymethylmethacrylate (PMMA) > polyacrylonitrile (PAN/AN69) > 
polysulfone (PS), polyester-polymer-alloy (PEPA) and cellulose-triacetate 
(CTA) (24). However, judging from the remarkable difference of β2M 
clearance between high-cut-off (cutoff 50–60 kDa) HD and conventional 
high-flow (cutoff 15–20 kDa) HD (25), the differences in sieving seem to 
be even more important for removal rates. 
Convective therapy 
In a retrospective study of more than 6000 individuals with a median 
observation period of about 2 years, Locatelli et al documented the 
superiority of convection (i.e., hemofiltration (HF) and hemodiafiltration 
(HDF)) compared to diffusion (i.e. conventional HD) in decreasing DRA 
morbidity and delaying the need for CTS surgery (26). Currently, several 
convective modalities (i.e., pre-/post-/mid- dilution HDF, on-line-/off-line 
HDF, pull and push HDF, double high-flux HDF) are available; 
additionally, high-flux HD and intermittent infusion HDF can be 
considered forms of “low-volume HDF”, in which convective exchange 
occurs via internal back-filtration within the dialyzer. All these modalities 
can remove β2M with great success compared with low-flux HD. Thus, the 
major determinants of β2M removal per session are membrane 
permeability, duration of treatment, and convective volume (27). 
Furthermore, the effective lowering of serum β2M levels by HDF as 
compared with low-flux HD is more prominent in patients without (vs. 
with) residual renal function (28).  
In recent decades, the targets of convective therapies have shifted to the 
removal of small proteins or protein-binding uremic toxins which are larger 
than β2M. Several randomized control trials (RCTs) studying, e.g., high-
flux versus low-flux (29-31) HD, HDF versus HD, and higher- versus 
lower-volume HDF, have shown certain favorable results for convective 
therapies and their higher volume in preventing erythropoietin-stimulating 
agent resistance, endothelial dysfunction, insufficient management of 
serum phosphate, intradialytic hypotension (32-34), as well as in reducing 
cardiovascular events/death and improving survival (35-40); meanwhile, 
there are no noteworthy prospective RCTs designed to examine the effect 
of convective therapies on the outcome of DRA.  
 
A few postmortem studies have shown that Aβ2M deposits in long-term 
HD patients are not specific to osteoarticular tissue; the main other organs 
involved have been the vascular walls, the heart, gastrointestinal tract and 
lungs (41). In the latest version of amyloid classification by the 
Nomenclature Committee of the International Society of Amyloidosis, the 
type of Aβ2M associated with DRA was modified from ‘localized’ to 
‘systemic’ (42).  
The hypothesis that β2M deposition, particularly in the blood vessels and 
heart, would also incite specific processes with pathogenic effects in the 
absence of extensive Aβ2M deposition was suggested in a review article 
(27). Indeed, this hypothesis explains the fact of favorable cardiovascular 
outcomes of higher convective therapy in patients even with relatively 
short dialysis periods compared to that of DRA onset. On the other hand, 
Uji et al demonstrated that a few intermediate forms of β2M, which were 
revealed by capillary electrophoresis, returned from the tissues and 
increased in the serum even after the use of online HDF treatments, 
suggesting that amyloidogenic β2M forms still cannot be removed by the 
current higher convective therapy (43).  
Intensive therapy  
Intensive regimens including nocturnal HD (8 hours, six night/week) and 
daily hemofiltration with high-flux membranes can remove 5- to 8-fold 
more β2M than conventional HD and decrease serum β2M levels 
significantly. Nevertheless, serum levels in these treatments do not reach 
the normal range (44, 45). Although a recent meta-analysis showed lower 
systolic blood pressure, increased hemoglobin levels and lower serum 
phosphate level in patients undergoing nocturnal HD compared with those 
undergoing conventional HD (46), there have been no RCTs examining the 
effect of intensive therapy on DRA outcomes. 
β2M-adsorptive apheresis 
A β2M-adsorbent column, Lixelle, which connects to a dialyzer in tandem 
for direct hemoperfusion for DRA, became commercially available in 
Japan in 1996, in Europe in 2013 and in USA in 2015. The inside of 
the column is composed of porous cellulose beads with a hydrophobic 
hexadecyl chain as a ligand. The determinants of the adsorption are both 
size and hydrophobicity; therefore, any hydrophobic molecule weighing 
4,000–20,000 g/mol can be adsorbed in the column; indeed, β2M 
(molecular weight 11,800 g/mol) is highly adsorbed . The column adsorbs 
various other molecules as well as β2M: numerous inflammatory cytokines 
(47), microbial fragments such as endotoxins and peptidoglycans, free light 
chains, myoglobin, bilirubin and drugs (digoxin, antibiotic agents); 
therefore, a synergistic effect of β2M elimination and anti-inflammatory 
effects is assumed.  
 
Treatments with Lixelle have been reported to be effective for improving 
both subjective symptoms, including joint pains and stiffness and activities 
of daily living (48-52), and objective findings such as pinch strength and 
the median motor terminal latency (48). Furthermore, decrease or arrest of 
bone cyst formation with significant β2M clearance was also reported (49, 
51); however, these studies were conducted in small numbers of patients 
and were evaluated at an early point within short-period treatments of 1–2 
years. Gejyo reported the results of a Japanese nationwide 
questionnaire survey from 345 patients who had used Lixelle; the mean 
durations of dialysis and Lixelle treatment were 25.9 ± 6.2 years and 3.5 ± 
2.7 years, respectively. Based on self-evaluation by patients, the worsening 
of symptoms was inhibited in 84.9–96.5%, suggesting that Lixelle 
treatment improved symptoms or prevented the progression of DRA in 
most patients (52).  
 
In the health insurance system in Japan, Lixelle cannot be used with HDF. 
From several case reports in Japan, even though the β2M removal rate was 
equivalent, HD with Lixelle was superior to convective therapy including 
online HDF and pull and push HDF in relieving joint pain. There are no 
RCTs comparing the effect of Lixelle with that of higher convective 
therapy; however, there may be differences in clinical indication between 
the two therapies. According to previous reports and expert opinions, 
Lixelle should be used in patients with severe joint symptoms, and/or in 
patients who have contraindications for higher convective therapy, such as 
those who are elderly, have malnutrition or chronic inflammation. In the 
latter case, the usage of low-flux and biocompatible membranes (i.e., 
PMMA and AN) are recommended.  
 
Prevention of inflammation and β2M production during hemodialysis 
Membrane biocompatibility 
Bioincompatible membranes such as cuprophane cause complement 
activation, followed by gene expression of inflammatory cytokines in 
peripheral blood cells (53). Evidence from both in vitro and in vivo studies 
suggests that cuprophane induces excessive β2M production(54, 55). 
Although these findings are not consistent (56), low-flux cuprophane 
membranes are  the most permeable to pyrogens from dialysate (57), 
which stimulates inflammation, leading to excessive β2M production.  
Dialysate  
Regarding the biocompatibility of the dialysate, elimination of acetate and 
sterilization have been two important issues. Acetate-containing dialysate 
can induce inflammatory cytokine production, peripheral vasodilatation, 
and suppression of myocardial function, resulting in intradialytic 
hypotension in HD patients. Several small-scale RCTs have been conducted 
and have discussed these symptoms, although their conclusions varied. 
Metabolic acidosis and higher plasma β2M levels were observed in HD 
patients using acetate-containing dialysate compared with bicarbonate-
containing dialysate. Metabolic acidosis may be relevant to  DRA. In 
normal men, NH4Cl loading increases β2M mRNA expression in 
lymphocytes (58). 
The use of ultrapure dialysate (UPD), one with almost no bacteria or 
endotoxins, as an important issue in the current era of highly convective 
therapy. In 226 long-term HD patients with cellulosic membranes, the 
prevalence of CTS onset was significantly lower in patients with UPD 
compared with non-UPD (59). Several studies have also demonstrated that 
the use of UPD correlates with a decrease of DRA (23 ,60). A recent meta-
analysis concluded that the use of UPD in HD patients  decreased markers 
of inflammation and oxidative stress, increased serum albumin and 
hemoglobin and decreased erythropoietin requirement (61); however, there 
is no information on DRA onset in this study. 
 
Current epidemiology of DRA 
There are two reports demonstrating that the prevalence of DRA has 
considerably decreased (9,10). In a single-center study from Germany in 
1997, Schwalbe et al reported the prevalence of DRA in 1988 versus 1996 
(9); randomly selected patients studied in 1988 were matched by time on 
HD (mean 71 months, range 3 to 207) and age (mean 51 years, range 22 to 
80) with patients of the 1996 population. Compared to the 1988 population, 
the 1996 population exhibited significantly lower prevalence of DRA in 
both CTS (1/43 vs 7/43) and bone cysts (positive patients, 3/43 vs. 13/43; 
possible sites, 7/272 33/272), and less home HD and more frequent usage 
of reverse osmosis water with bicarbonate buffer than acetate for dialysate 
preparation. No difference in serum β2M levels between the two groups 
was evident, and the proportion of time occupied by high-flux synthetic 
membranes usage in total dialysis time was quite low in both groups (13% 
of 1996 and 6% of 1988). The author speculated that β2M removal is 
unlikely to be the source of the remarkable decrease of DRA, and that other 
factors, for example, dialysate composition and purity, may be involved.  
 
Recently, we documented the updated epidemiology of DRA based on the 
national registry data from Japanese Society for Dialysis Therapy (JSDT) 
(10). We retrospectively compared the incidence of first-time CTS surgery 
as a proxy for DRA onset in 1998 (n=36,489) versus 2010 (n=166,237) 
cohorts (Fig. 1). The incidence of first-time CTS surgery was significantly 
higher in the 1998 cohort than in the 2010 cohort (1.77% versus 1.30%, 
adjusted OR 2.22 (1.68-2.95)). This favorable result of the 2010 cohort 
compared with the 1998 cohort was most prominent in patients with longer 
dialysis periods, younger age and lower pre-HD β2M (Fig. 2). Using this 
2010 cohort, we showed that other factors associated with CTS besides 
dialysis duration were age, gender, serum albumin, and diabetic 
nephropathy. We also indicated that β2M clearance >80% may contribute 
to decrease the incidence of CTS (62) (Fig. 3). 
 According to the latest Japanese national registry data from JSDT at the 
end of 2016, the prevalence of dialysis patients who used Lixelle or another 
adsorptive dialyzer (i.e., AN69 membranes) was only 0.43% 
(1,355/318,814). However, as dialysis vintage increased, the value 
increased; 1.8 (230/12,484), 4.1 (284/6,897), 8.0 (317/3,987), 10.3 
(222/2,152), and 11.5% (91/793) for dialysis vintage of 20-25, 25-30, 30-
35, 35-40, and ≥40 years, respectively. 
Although long-term survival of HD patients may increase the incidence of 
delayed onset DRA, the technological improvement of HD certainly has 
decreased the incidence of early onset DRA. 
Conclusions 
The great success of HD in removing β2M (or some β2M-associated 
molecules) seems to be a major contributor to the delay of DRA onset, but 
this is still a controversial hypothesis. Again, DRA is a disease that 
develops only in ESRD patients in whom β2M has accumulated 
remarkably in the body. Even if serum β2M levels cannot be lowered, 
better removal of β2M can inhibit irreversible deposition into tissues by 
maintaining a dynamic equilibrium between the serum and tissue. 
Additionally, the improved biocompatibility of both membranes and 
dialysates minimizes β2M production and inflammation, which could also 
help prevent the development and progression of DRA. 
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Figure legends 
Fig. 1  Comparison of CTS new incidence rates in cohorts from 1998 and 
2010 in Japan. The incidence of first-time CTS surgery was significantly 
higher in 1998 than in the 2010 (1.77% versus 1.30%). adapted 
from Hoshino J, Yamagata K: Significance of the decreased risk of dialysis-
related amyloidosis now proven by results from Japanese nationwide 
surveys in 1998 and 2010. Nephrol Dial Transplant. 2016; 31: 595-602 
(reference 10). Used with permission of the ERA-EDTA 
 
Fig. 2 Adjusted OR of CTS onset in the two populations in 1998 and 2010, 
by dialysis duration (A), age (B), pretreatment serum β2m (C) and β2m 
clearance (D). ORs were adjusted by dialysis duration, age, sex, primary 
kidney disease, modality, body mass index, albumin, CRP, Kt/V, 
normalized PCR and β2m clearance. In the analysis including pre-dialysis 
β2m, β2m removal was used instead of β2m clearance. adapted 
from Hoshino J, Yamagata K: Significance of the decreased risk of dialysis-
related amyloidosis now proven by results from Japanese nationwide 
surveys in 1998 and 2010. Nephrol Dial Transplant. 2016; 31: 595-
602 (reference 10). Used with permission of the ERA-EDTA 
 
Fig. 3 Adjusted ORs of CTS onset. ORs were adjusted by dialysis duration, 
age, gender, primary kidney disease, history of smoking, history of 
hypertension, dialysis modality, use of high-flux membrane, BMI, serum 
albumin (Alb), Kt/V, nPCR, and serum β2MG clearance. CGN, chronic 
glomerulonephritis; DM, diabetic nephropathy; ADPKD, autosomal 
dominant polycystic kidney disease; SLE, systemic lupus 
erythematosus. adapted from Hoshino J, Yamagata K: Carpal tunnel 
surgery as proxy for dialysis-related amyloidosis: results from the Japanese 
Society for Dialysis Therapy. Am J Nephrol. 2014; 39: 449-458 (reference 
62). Used with permission of S. Karger AG 
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